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Abstract 
The clinicopathologic features of 472 ovarian epithelial clear cell neoplasms (4 adenofibromas [AFs], 41 
atypical proliferative [borderline] tumors [APTs], and 427 carcinomas [CAs]) were studied in order to 
elucidate the morphologic steps involved in the pathogenesis of these tumors and determine whether 
clear cell CA is a type I or type II tumor in the dualistic model of ovarian carcinogenesis. Thirty-three 
percent of the CAs had an adenofibromatous background [CA(AF+)], and 67% did not [CA(AF-)]. En-
dometriosis was found in all types of tumors, but tumors arising in endometriotic cysts were more 
frequent with CA(AF-)s (p<0.0001). The subset of women with CA(AF-)s with endometriosis were 
younger (p<0.0001), their tumors were more frequently cystic (p<0.0001), they more commonly had a 
mixed carcinoma component of non-clear cell type (p=0.006), and they were more frequently oxyphilic 
(p=0.015) compared with CA(AF+)s. The architecture of the former tumors was more commonly pa-
pillary compared to tubulocystic in the latter (p=0.0006). Atypical endometriosis was more common in 
CA(AF-)s than in AFs, APTs, and CC(AF+)s [p=0.004]. The subset of CA(AF-)s without endometriosis 
presented more frequently in advanced stage (>I) and were higher grade compared to CA(AF+)s or 
CA(AF-) with endometriosis (p-values, <0.0001 to 0.0071). All AFs and APTs were stage I compared to 
79% of CA(AF+)s. An increase in mean tumor size correlated with each respective tumor category from 
AF (6.8 cm) to CA(AF+) [12.9 cm]. Notable nuclear atypia was absent in all AFs but was focally present 
in 27% of APTs and in the adenofibromatous background of 24% of the CA(AF+)s. An increase in the 
proportion of carcinoma in the CA(AF+)s correlated with an increase in grade and advanced stage. In 
summary, ovarian clear cell CA appears to develop along two pathways, both of which are related to 
endometriosis. We speculate that, in one, epithelial atypia arises in an endometriotic cyst and then 
evolves into clear cell CA, and, in the other, non-cystic endometriosis induces a fibromatous reaction 
resulting in the formation of AF, which then develops into APT and subsequently a clear cell CA. The 
absence of endometriosis or adenofibromatous components in CC(AF-)s may be due to overgrowth and 
obliteration by the invasive carcinoma. Finally, the findings in this study support the view that both types 
of clear cell CA [CC(AF+) and CC(AF-)] are more closely related to type I tumors. 
Key words: Ovary; clear cell carcinoma; adenofibromatous; endometriosis; pathogenesis. 
INTRODUCTION 
The  dualistic  model  of  ovarian  carcinogenesis 
divides epithelial tumors into two groups designated 
type I and type II.40,41,59 Type I tumors are generally 
low-grade and include low-grade serous carcinoma, 
endometrioid  carcinoma,  mucinous  carcinoma,  and 
malignant Brenner tumor. They present in low stage, Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
95 
behave in an indolent fashion, are characterized by 
mutations  of  KRAS,  BRAF,  PTEN,  and/or  CTNNB1 
and/or microsatellite instability, and display a rela-
tively low level of chromosomal instability. They de-
velop  in  a  slow  step-wise  fashion  from 
well-established precursor lesions such as cystadeno-
fibroma and borderline tumors. In contrast, the type II 
tumors are high-grade and include high-grade serous 
carcinoma,  transitional  cell  carcinoma,  malignant 
mesodermal mixed tumor, and undifferentiated car-
cinoma.  They  are  highly  aggressive,  present  in  ad-
vanced  stage,  have  a  very  high  frequency  of  TP53 
mutations, and display a high level of chromosomal 
instability.  They  are  not  associated  with  the  usual 
precursor lesions, and a proportion develop from in-
traepithelial carcinomas in the fallopian tube.  
The pathogenesis  of clear cell carcinoma (CA), 
however, is enigmatic and does not perfectly fit into 
this model because it has features shared with both 
type I and type II tumors. For example, like some type 
I tumors, clear cell CA is associated with endometrio-
sis, adenofibromas (AFs)/atypical proliferative [bor-
derline]  tumors  (APTs);  low-stage  disease;  variable 
frequency of mutations of PIK3CA, KRAS, and PTEN 
and  microsatellite  instability;  low  frequency  of  p53 
mutations; and low to moderate level of chromosomal 
instability.8,9,14,19,25,32,37,38,40,56,59,65,70,71,75  However,  simi-
lar to type II tumors, clear cell CA is high-grade and 
associated  with  poor  behavior  when  it  is  of 
high-stage.8,20,24,25,44,58,64,66  
Although  numerous  epidemiologic,  clini-
cal/radiologic, histologic, immunohistochemical, and 
molecular studies have provided compelling evidence 
that  endometriosis/endometriotic  cysts  are  precur-
sors  of  clear  cell 
CA,2,3,5-7,10,12,15,17,20,21,23,26-36,39,42,43,45-50,53,54,57,63,67,69,70,72,75,76 
the exact pathogenic relationship of clear cell AF/APT 
with  CA  is  ambiguous.  Reports  of  small  clear  cell 
CAs/microinvasion arising in APT, the presence of an 
adenofibromatous background within clear cell CA, 
and molecular data showing (a) a clonal relationship 
between clear cell AF, APT, and CA and (b) tumor 
progression  of  AF/APT  all  suggest  an  adenofibro-
ma-carcinoma  sequence.4,30,55,70,74,75,77  Some  studies 
have  demonstrated  clinicopathologic  and  molecular 
differences  between  endometriosis-associated  clear 
cell CAs, which are commonly cystic, and those con-
taining  an  adenofibromatous  background  and  pro-
posed  that  each  may  have  a  different  pathogene-
sis.70,73,75 However, the numbers of adenofibromatous 
CAs  in  these  studies  are  relatively  small,  and  this 
model implies that both pathways are independent of 
one another although some adenofibromatous tumors 
can be associated with endometriosis.4,46,55,70,75,77 Thus, 
the  relationship  between  endometriosis-associated 
and adenofibromatous pathways of development of 
clear cell CA, as well as the pathogenesis of clear cell 
AF  or  APT,  are  unclear,  and  the  clear  cell  adeno-
fibroma-carcinoma sequence is poorly understood. 
In  order  to  better  elucidate  the  morphologic 
steps involved in the pathogenesis of ovarian epithe-
lial clear cell tumors and determine whether clear cell 
CA is a type I or type II tumor, we studied the clini-
copathologic  features  of  472  ovarian  clear  cell  AFs, 
APTs, and CAs, the largest investigation of this kind 
to date. 
MATERIALS AND METHODS 
The study was performed with approval of the 
Institutional Review Board at the Armed Forces In-
stitute of Pathology (AFIP). All ovarian tumors orig-
inally  diagnosed  as  clear  cell  AF,  APT/borderline 
tumor /tumor of low malignant potential, and clear 
cell CA from 1971 to 2004 were retrieved from the files 
of  the  AFIP  in  Washington,  D.C.  (n=495),  and  all 
available H&E slides were re-reviewed. Tumors were 
subclassified as AF, APT, and CA. Diagnostic criteria 
for AF and APT were based on those used by Bell and 
Scully and Roth et al.4,55 Although criteria for the dis-
tinction of clear cell AF/APT from CA have not been 
firmly established, cases showing haphazard infiltra-
tive growth or  single cells within  stroma combined 
with  desmoplastic,  myxoid/edematous,  or  inflam-
matory stromal alterations were classified as CA. For 
cases not exhibiting classic forms of destructive stro-
mal invasion, confluent architecture in solid tumors or 
complex growth in intra-cystic tumors was also con-
sidered  a  pattern  of  CA. Furthermore,  tumors  with 
AF-like  architecture  but  lacking  typical  patterns  of 
stromal  invasion  were classified as CA if the histo-
logic features significantly exceeded that of the con-
ventional appearance of clear cell AF or APT. Tumors 
not qualifying as an epithelial clear cell tumor (AF, 
APT, or CA) after re-review were excluded. Also, CAs 
with clear cytoplasm that did not contain any classic 
architectural  and  cytologic  features  of  ovarian  clear 
cell CA61 were not included. After re-review, 23 cases 
were excluded; thus, 472 cases were the subject of this 
study.  
Clinical  data  and  gross  information  were  ex-
tracted from operative notes and the original pathol-
ogy reports, respectively. FIGO stage was based on a 
combination  of  clinical  data,  information  from  the 
original pathology report, and review of H&E slides 
of  non-ovarian  tissues.  A  FIGO  stage  was  assigned 
only  for  cases  in  which  there  were  sufficient 
non-ovarian  tissues  available  for  histologic  review, 
which included variable combinations of slides from Journal of Cancer 2011, 2 
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salpingo-oophorectomies,  hysterectomies, 
omentectomies, lymph node dissections, and staging 
biopsies. Clinical follow-up for a sufficient number of 
cases was not available. Requests were sent to clini-
cians,  but  too  few  responses  were  received;  thus, 
meaningful statistical analysis for follow-up was not 
possible. However, the staging data were compared 
between tumor categories. 
The frequency of endometriosis, which included 
both endometriotic implants and endometriotic cysts 
(endometriomas),  its  location,  and  presence  or  ab-
sence of cytologic atypia were recorded. The designa-
tion “endometriosis anywhere” included endometri-
osis  within  the  ovarian  tumor,  residual  ipsilateral 
normal ovarian tissue, the contralateral normal ovary, 
or extra-ovarian sites; however, the frequency of en-
dometriosis was based only on cases in which tissues 
other than the ovarian tumor were removed. Endo-
metriosis in the ovarian tumor was designated as such 
if it was present either within the tumor itself or in 
adjacent residual ipsilateral normal ovarian tissue. As 
definitive  criteria  for  the  distinction  of  atypical  en-
dometriosis  from  either  benign  degenera-
tive/metaplastic changes  or intraepithelial clear cell 
CA in endometriosis have not been validated, as well 
as that this morphologic distinction is unlikely to be 
reproducible, notable epithelial atypia in endometrio-
sis was not further classified in this study. 
 Epithelial  atypia  within  AFs  or  APTs  was  as-
sessed. As intraepithelial CA in clear cell tumors has 
not  been  stringently  defined,  that  terminology  was 
not  used,  and  no  attempt  was  made  to  determine 
which  atypical  foci  represented  intraepithelial  CA. 
Thus,  notable  atypia,  which  was  not  unequivocally 
clear cell CA, was simply recorded as present or ab-
sent.  
CAs  were  assessed  for  various  histologic  fea-
tures,  including  grade  and  an  adenofibromatous 
background. The type of architectural pattern (tubu-
locystic, papillary, glandular, solid) was recorded and 
categorized as pure if it composed >90% of the tumor 
and mixed if >10% of a second type was present. The 
presence of other tumor types was noted and desig-
nated  “mixed  carcinoma”  if  the  non-clear  cell  com-
ponent accounted for >10% of the tumor.  
CAs  were  assigned  a  histologic  grade  using  a 
modification  of  the  universal  grading  sys-
tem/“Silverberg grade”60,62 as follows: The architec-
tural  score  was  based  on  the  proportion  of  solid 
growth- 1 point, <5%; 2 points, 6-50%; and 3 points, 
>50%.  The  predominating  nuclear  score  was  deter-
mined- 1 point, uniform nuclei with smooth nuclear 
contours  and  inconspicuous  nucleoli;  2  points,  en-
larged nuclei with hyperchromasia, increased nucle-
ar-to-cytoplasmic  ratios,  and  nucleoli  visible  under 
high-power  (40x  objective)  magnification;  and  3 
points,  marked  cytologic  atypia,  large  nuclei,  and 
usually vesicular chromatin with prominent nucleoli. 
The mitotic score in the most mitotically active area of 
the tumor was based on the number of mitotic figures 
(MFs) per 10 high-power fields (HPFs) [40x objective 
field area, 0.237 mm2) per the highest count method- 1 
point, 0-2 MFs/10 HPFs; 2 points, 3-7 MFs/10 HPFs; 
and 3 points, >8 MFs/10 HPFs. Points for each score 
were summed, and the final grade was determined as 
follows: Grade 1, 3-5 points; grade 2, 6-7 points; and 
grade 3, 8-9 points. These grading criteria depart from 
the original scheme60,62 (different architectural criteria 
and lower mitotic index cut-points) in order to allow 
for simplistic architectural grading (analogous to that 
for endometrial carcinoma) and because ovarian clear 
cell CAs typically have low mitotic indices.  
CAs were subclassified as those with and with-
out an adenofibromatous background [CA(AF+) and 
CA(AF-),  respectively],  and  their  clinicopathologic 
features were compared. The background of the CA 
was  considered  “adenofibromatous”  if  it  had  histo-
logic features of an AF or APT. In addition to grading 
the CA, the presence of atypia in the adenofibroma-
tous  component  of  the  tumor  was  recorded  in  the 
same fashion as for AFs and APTs.  
All  statistical  analyses  were  performed  in  SAS 
version 9.2 (SAS institute, Inc.; Cary, NC, USA), and 
the significance level was set at 0.05. Ranges and fre-
quency distributions of all continuous and categorical 
variables  were  examined.  The  t-test  was  used  to 
compare the mean differences in age and tumor size. 
Chi-square  or  Fisher  exact  tests  were  applied  for 
comparison  of  stage,  bilaterality,  gross  appearance, 
grade,  architectural  pattern,  mixed  carcinoma  com-
ponent, presence of oxyphilic features, and categories 
of endometriosis.  
RESULTS 
Clear Cell Adenofibroma (n=4)  
 The  clinicopathologic  features  with  respect  to 
age, stage, bilaterality, tumor size, and gross appear-
ance are shown in Table 1. Histologically, the tumors 
were composed of glands separated by abundant fi-
bromatous stroma (Fig. 1). The glands were typically 
small to medium in size, mostly round, uniform in 
size and shape, and occasionally filled with eosino-
philic secretions. They were lined by 1 or 2 layers of 
flat to low-cuboidal cells with scant to moderate pale 
or  clear  cytoplasm.  The  nuclei  were  usually  small, 
uniform, and flat to round. The nuclei exhibited either 
no or mild atypia, but notable nuclear atypia was not Journal of Cancer 2011, 2 
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present in any case. Mitotic figures were not identi-
fied.  Associations  with  endometriosis  are  shown  in 
Tables 2 and 3.  
 
Figure 1  Clear cell adenofibroma. Simple glands lined by 
non-atypical flat cells are separated by abundant fibroma-
tous stroma. The glands are cystically dilated and filled with 
eosinophilic secretions. 
 
TABLE 1: Clinicopathologic features of clear cell adeno-
fibroma and atypical proliferative (borderline) clear cell 
tumor
* 
Clinicopathologic feature  Adenofibroma 
(n=4) 
Atypical proliferative 
(borderline) tumor 
(n=41) 
Mean patient age (years) 
[range] 
61 
(50-75) 
60 
(30-85) 
Stage I  2/2 
(100%) 
15/15 
(100%) 
Stage >I  0/2 
(0%) 
0/15 
(0%) 
Bilateral  0%  1  
(2%) 
Mean tumor size (cm) 
[range] 
6.8 
(4-9) 
9.0 
(2-20) 
 
Cystic† 
0%  4 
(10%) 
Mixed cystic and solid†  1 
(25%) 
31 
(76%) 
Solid†  3 
(75%) 
6 
(15%) 
*, The denominator for all calculations is based on the total number 
in that patient group unless specified otherwise 
†, Predominant gross appearance 
 
TABLE 2: Endometriosis associated with ovarian clear cell neoplasms
 
Location of endometriosis Adenofibroma 
(n=4) 
Atypical proliferative 
(borderline) tumor 
(n=41) 
Carcinoma with adeno-
fibromatous background 
(n=141) 
Carcinoma without adeno-
fibromatous background 
(n=286) 
p-value* 
Endometriosis anywhere  1/2 
(50%) 
7/35 
(20%) 
33/130 
(25%) 
87/268 
(32%) 
0.078 
Endometriosis in ovarian 
tumor 
0%  6 
(15%) 
16 
(11%) 
57 
(20%) 
0.02 
Tumor arising directly 
within endometriotic cyst 
0%  1 
(2%) 
6 
(4%) 
46 
(16%) 
<0.0001 
*, All adenofibromatous tumors combined (adenofibroma + atypical proliferative [borderline] tumor + carcinoma with adenofibromatous 
background) vs. carcinoma without adenofibromatous background 
TABLE 3: Atypical endometriosis in ovarian clear cell neoplasms
* 
Adenofibroma  Atypical proliferative (borderline) tu-
mor 
(n=6) 
Carcinoma with adenofibrom-
atous background 
(n=16) 
Carcinoma without adeno-
fibromatous background 
(n=57) 
p-value† 
-  1 
(17%) 
2 
(13%) 
25 
(44%) 
0.004 
*, The denominator for all calculations is based on the number of patients in that group with typical or atypical endometriosis in the ovarian 
tumor 
†, All adenofibromatous tumors combined (atypical proliferative [borderline] tumor + carcinoma with adenofibromatous background) vs. 
carcinoma without adenofibromatous background 
 
Atypical Proliferative (Borderline) Clear Cell 
Tumor (n=41)  
The  clinicopathologic  features  with  respect  to 
age, stage, bilaterality, tumor size, and gross appear-
ance are shown in Table 1. Histologically, the tumors 
contained a background of AF and exhibited greater 
glandular crowding as well as more variation in size 
and  shape  of  glands,  including  cystic  dilatation, 
compared  with  AFs  (Fig.  2A).  Occasional  glands 
showed slightly more stratification of the epithelium 
(2-4  layers)  but  generally  did  not  have  substantial 
architectural complexity, such as papillary, solid, or 
cribriform  patterns.  The  nuclei  were  mostly  small, 
uniform, and flat to round but occasionally had mild 
nuclear enlargement and slight hyperchromasia; nu-
cleoli, if present, were usually small (Fig. 2B).  
 Journal of Cancer 2011, 2 
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Figure 2  Atypical  proliferative  (borderline)  clear  cell 
tumor. (A) The glands show a greater degree of crowding 
and variation in size and shape compared with clear cell 
adenofibroma. (B) The glands in many areas are lined by flat 
non-atypical cells. (C) Focal notable nuclear atypia is pre-
sent in the glandular epithelium. 
 
 
 
Only  one  case  had  mitotic  activity  (1  MF/10 
HPFs). Notable nuclear atypia was focally present in 
11  (27%)  cases  (Fig.  2C);  however,  such  foci  lacked 
associated stromal alterations and recognizable forms 
of  invasion,  such  as  an  haphazard  infiltration  of 
glands, glandular confluence, mitotic activity within 
glands, or the conventional appearance of clear cell 
CA.  
Associations  with  endometriosis  are  shown  in 
Tables 2 and 3. Foci of atypia in endometriosis in the 
ovarian  tumor  were  characterized  by  nuclear  en-
largement,  hyperchromasia,  and  occasional  hobnail 
morphology of the endometriotic epithelium, but ar-
chitectural features of CA in such foci were absent. 
Clear Cell Carcinoma with Adenofibromatous 
Background (n=141) 
The  clinicopathologic  features  with  respect  to 
age, stage, bilaterality, tumor size, gross appearance, 
and distributions of grade and architectural pattern 
are shown in Table 4. Between cases, the CAs histo-
logically displayed combinations of tubulocystic (Fig. 
3A), papillary, and solid architectural patterns; hob-
nail, polygonal, and flat cell shapes (Fig. 3B); clear or 
oxyphilic  cytoplasm;  a  spectrum  of  atypia  ranging 
from  mild  to  severe;  generally  low  mitotic  indices; 
and hyalinized stroma, similar to the features seen in 
ovarian  clear  cell  CAs  described  in  detail  else-
where.13,47,70,75,77  
The background of the tumor contained variable 
amounts of adenofibromatous components (Fig. 3C). 
The proportion of the clear cell CA component in the 
tumors ranged from focal to diffuse, but cases with 
focal CA components exceeded conventional defini-
tions  for  microinvasion  (>3  mm  in  greatest  dimen-
sion). Notable nuclear atypia was focally present in 
the adenofibromatous background in 34 (24%) cases, 
and the histologic appearance of such foci was similar 
to those with notable atypia in APTs described above. 
A comparison with non-adenofibromatous clear cell 
CAs is shown in Table 4. 
Although the vast majority of tumors displayed 
overt carcinomatous growth patterns, the architecture 
of the entire tumor in 7 (5%) cases superficially re-
sembled an AF/APT with fibromatous and unaltered 
stroma between glands; however, the combined de-
gree of glandular crowding and variation in size and 
shape  of  the  glands,  haphazard  arrangement  of 
glands, substantial epithelial stratification, and diffuse 
marked atypia significantly exceeded the convention-
al appearance of AF/APT (Fig. 4). In the 6 cases with 
staging data, 1 (17%) had extra-ovarian disease. 
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TABLE 4: Clinicopathologic features of ovarian clear cell 
carcinomas
* 
Clinicopathologic 
feature 
Carcinoma with aden-
ofibromatous back-
ground 
(n=141) 
Carcinoma with-
out adenofibrom-
atous background 
(n=286) 
p-value 
Mean patient age 
(years) 
[range] 
57 
(21-83) 
52 
(22-84) 
0.0001 
Stage I  85/107  
(79%) 
121/213  
(57%) 
<0.0001 
Stage >I  22/107  
(21%) 
92/213  
(43%) 
Bilateral   7 
(5%) 
22 
(8%) 
0.29 
Mean tumor size 
(cm) 
[range] 
12.9 
(2-30) 
12.3 
(2-40) 
0.36 
Cystic†  30/138 
(22%) 
120/282 
(43%) 
0.0002 
Cystic and solid†  75/138 
(54%) 
115/282 
(41%) 
Solid†  33/138 
(24%) 
47/282 
(17%) 
 
Grade 1 
51 
(36%) 
72 
(25%) 
<0.0001 
Grade 2  70 
(50%) 
91 
(32%) 
Grade 3  20 
(14%) 
123 
(43%) 
Tubulocystic§  38 
(27%) 
20 
(7%) 
<0.0001 
Glandular§  3 
(2%) 
5 
(2%) 
Solid§  2 
(1%) 
43 
(15%) 
Papillary§  6 
(4%) 
27 
(9%) 
Mixed  92 
(65%) 
191 
(67%) 
Mixed carcinoma 
component of 
non-clear cell 
type 
6 
(4%) 
29 
(10%) 
0.04 
*, The denominator for all calculations is based on the total number 
in that patient group unless specified otherwise 
†, Predominant gross appearance 
§, Pure architectural pattern 
 
 
Figure 3  Carcinoma  with  adenofibromatous  back-
ground.  The  carcinoma  component  exhibits  a  (A)  tubu-
locystic pattern with (B) oxyphilic, hobnail, and flat atypical 
cells. (C) The adenofibromatous component does not show 
architectural features of clear cell  carcinoma or notable 
atypia. Journal of Cancer 2011, 2 
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Figure 4  Clear  cell  carcinoma  with  adenofibroma-like 
growth pattern. (A) The glands are separated by fibroma-
tous stroma, but the extent and degree of epithelial pro-
liferation is consistent with clear cell carcinoma despite the 
lack of an altered stromal response. (B) Separate focus from 
the same case showing marked crowding of tubules with 
slightly haphazard arrangement. The size and shape of the 
tubules are markedly different compared with Fig. 4A. 
 
 
 
 
Associations  with  endometriosis,  including 
comparison  with  non-adenofibromatous  clear  cell 
CAs, are shown in Tables 2, 3, and 5. Foci of epithelial 
atypia  in  endometriosis  in  the  ovarian  tumor  were 
similar to those in atypical endometriosis associated 
with APTs noted above. 
Comparison of AFs, APTs, and CA(AF+)s (Table 
6) revealed that all AFs and APTs were stage I as were 
79% of CA(AF+)s. The tumor categories from AF to 
CA correlated with a gradual increase in tumor size. 
Increasing proportions of the CA component in the 
CA(AF+)s correlated with a slight increase in grade 
and advanced stage (Table 7).   
 
TABLE 5: Association of adenofibromatous background 
and endometriosis in ovarian clear cell carcinoma (n=427) 
Clear Cell Carcinoma-Associated Compo-
nents 
Frequency 
Adenofibromatous background (+) 
Endometriosis (+) 
16 
(4%) 
Adenofibromatous background (+) 
Endometriosis (-) 
125 
(29%) 
Adenofibromatous background (-) 
Endometriosis (+) 
57 
(13%) 
Adenofibromatous background (-) 
Endometriosis (-) 
229 
(54%) 
 
 
TABLE 6: Stage and size of clear cell adenofibromatous 
tumors
* 
Clinicopathologic 
feature 
Adenofibroma 
(n=4) 
Atypical 
proliferative 
(borderline) 
tumor 
(n=41) 
Carcinoma with  
adenofibromatous  
background 
(n=141) 
Stage I  2/2 
(100%) 
15/15 
(100%) 
85/107 
(79%) 
Stage >I  0/2 
(0%) 
0/15 
(0%) 
22/107  
(21%) 
Mean tumor size 
(cm) 
[range] 
6.8 
(4-9) 
9.0 
(2-20) 
12.9 
(2-30) 
*, The denominator for all calculations is based on the total number 
in that patient group unless specified otherwise 
 
TABLE 7: Stage and grade of clear cell carcinomas with 
adenofibromatous background based on proportion of 
carcinoma component
* 
Clinicopathologic fea-
ture 
Carcinoma with adenofibromatous back-
ground:  
percentage of tumor composed of carcino-
ma component 
(n=141) 
<50% 
(n=42) 
50-75% 
(n=30) 
>75% 
(n=69) 
Stage I  32/36 
(89%) 
16/20 
(80%) 
37/51 
(73%) 
Stage >I  4/36 
(11%) 
4/20 
(20%) 
14/51 
(27%) 
 
Grade 1 
21 
(50%) 
9 
(30%) 
21 
(30%) 
Grade 2  18 
(43%) 
16 
(53%) 
36 
(52%) 
Grade 3  3 
(7%) 
5 
(17%) 
12 
(17%) 
*, The denominator for all calculations is based on the total number 
in that patient group unless specified otherwise 
 
Clear Cell Carcinoma without Adenofibroma-
tous Background (n=286) 
 The  clinicopathologic  features  with  respect  to 
age, stage, bilaterality, tumor size, gross appearance, 
and distributions of grade and architectural pattern 
are shown in Table 4. The histologic appearance was 
similar  to  that  of  the  CA  components  of  CA(AF+). 
Complex intra-cystic growth without destructive in-
vasion  of  underlying  normal  ovarian  stroma  was Journal of Cancer 2011, 2 
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common  (Fig.  5).  Twenty-nine  tumors  (10%)  had  a 
mixed carcinoma component of non-clear cell type, 9 
of  which  were  associated  with  endometriosis.  A 
comparison with adenofibromatous clear cell CAs is 
shown in Table 4. 
 Associations  with  endometriosis,  including 
comparison with adenofibromatous clear cell CAs, are 
shown in Tables 2, 3, and 5. The 57 CAs with endo-
metriosis in the ovarian tumor had the following his-
tologic patterns: tubulocystic (n=4), glandular (n=1), 
solid (n=4), and papillary (n=8). Mixed patterns oc-
curred in 40. Thirty-one of the 46 (67%) cases arising 
directly within an endometriotic cyst had a predomi-
nantly  cystic  gross  appearance.  Foci  of  epithelial 
atypia  in  endometriosis  in  the  ovarian  tumor  were 
similar  to  those  in  endometriosis  associated  with 
APTs noted above (Figs. 6 and 7).  
 
 
Figure 5  Clear  cell  carcinoma  arising  within  an  endo-
metriotic cyst. The tumor is entirely intra-cystic.   
 
Figure 6  Clear  cell  carcinoma  arising  within  an  endo-
metriotic cyst. Typical endometriotic epithelium (bottom) 
gradually shows greater atypia (middle) as it merges with 
possible intraepithelial carcinoma (top) and intra-cystic clear 
cell carcinoma (left).  
 
Figure 7  Atypical  endometriotic  cyst  associated  with 
clear cell carcinoma. (A) The endometriotic cyst contains 
scattered atypical epithelial cells, which were not directly 
contiguous with the carcinoma (not shown). (B) The atypical 
cells  have  round  nuclei  and  abundant  eosinophilic  cyto-
plasm. Some atypical nuclei are hyperchromatic whereas 
others have irregularly distributed chromatin. 
 
Comparison of Clear Cell Carcinomas (without 
an Adenofibromatous Background) with Endo-
metriosis vs. Other Tumors 
 Within  the  entire  category  of  CC(AF-)s,  the 
subset associated with endometriosis in the ovarian 
tumor emerged as a distinct subset. Compared with 
all  other  clear  cell  CAs  [CC(AF+)s  and  CC(AF-)s 
without  endometriosis  combined],  women  with 
CC(AF-)s with endometriosis were younger (p=0.001), 
and their tumors were more often cystic (p<0.0001) 
and stage I (p=0.02). Also, they more commonly had a 
mixed  carcinoma  component  of  non-clear  cell  type 
(p=0.04),  endometriosis  in  the  ovarian  tumor 
(p<0.0001), and tumor arising directly within an en-
dometriotic cyst (p<0.0001). When endometriosis was 
present in any category of clear cell CA, it was more 
commonly  atypical  in  CC(AF-)  with  endometriosis 
(p=0.004).  Differences  for other  parameters,  such  as 
tumor  size,  grade,  architecture,  and  oxyphilic  fea-Journal of Cancer 2011, 2 
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tures, were not statistically significant (p-values, 0.10 
to 0.42). 
DISCUSSION 
This study and others confirm that there are two 
distinctive forms of clear cell carcinoma based on a 
number  of  differing  clinicopathologic  features-  one 
associated  with  an  adenofibromatous  background 
[CC(AF+)] and the other  without an adenofibroma-
tous  background  [CC(AF-)].70,75  Although  endome-
triosis  can  be  seen  in  some  CC(AF+)s,  it  is  signifi-
cantly more common in CC(AF-)s. In contrast to all 
the  other  types  of  clear  cell  CAs,  the  subset  of 
CC(AF-)s with endometriosis is particularly distinc-
tive since the women with these tumors are younger 
and their tumors are lower stage and cystic, as they 
develop  within  an  endometriotic  cyst  (endometrio-
ma). Previous studies with relatively small numbers 
of CA(AF+)s have suggested that the pathogenesis of 
clear cell CA is related to endometriosis in some cases 
and to AFs in others and that both endometriosis and 
AFs  are  precursors.  In  a  study  by  Yamamoto  et al, 
CA(AF+)s more commonly had a lower grade, tubu-
locystic architecture, a lower Ki-67 proliferation index, 
and better overall survival and less frequently were 
associated  with  endometriosis  compared  with 
CA(AF-)s.75 Cystic clear cell CAs were strongly asso-
ciated with endometriosis and tended not to have an 
adenofibromatous background in a study by Veras et 
al.70  In  that  study,  CA(AF+)s  were  predominantly 
tubulocystic  in  architecture  and  of  higher  stage  in 
contrast with cystic CAs, which were more often pa-
pillary and had better survival. A study comparing 
loss  of  heterozygosity  (LOH)  between  endometrio-
sis-associated  clear  cell  CAs  and  CA(AF+)s  demon-
strated significantly higher frequencies of LOH at 3p, 
5q,  and  11q  in  the  former.73  Indeed,  these  studies 
coupled  with  the  findings  from  our  study,  which 
represents  the  largest  morphologic  investigation  of 
adenofibromatous clear cell CAs to date, confirm this 
concept of two pathways of tumor development.  
 In  our  study,  the  three  categories  of  adeno-
fibromatous tumors [AF, APT, and CA(AF+)], as well 
as the AF, APT, and CA components in CA(AF+)s, 
represented  a  continuous  morphologic  spectrum. 
Some CA(AF+)s predominantly displayed only mild 
atypia,  and  a  subset  of  CA(AF+)s  had  architectural 
patterns resembling AFs or APTs. In particular, the 
adenofibromatous  tumors  [AF,  APT,  and  CA(AF+)] 
showed a direct relationship between tumor type and 
stage, size, and atypia in the adenofibromatous back-
ground. Also, the proportion of the CA component in 
CA(AF+)s correlated with stage and grade. In a study 
of  adenofibromatous  clear  cell  tumors  containing 
these  three  components  by  Yamamoto  et  al,  each 
component displayed progressively higher Ki-67 pro-
liferation indices, respectively.72 In another study by 
the  same  investigators,  each  of  the  three  clear  cell 
components frequently shared LOH on 5q, 10q, and 
22q.74 The overall frequency of LOH in each compo-
nent increased from AF to CA, respectively. LOH on 
1p and 13q was rare in the AF/APT components but 
common in the CA component. Also, the APT com-
ponents  showed  a  higher  frequency  of  LOH  at  1p 
compared with the AF component. All of these find-
ings are consistent with tumor progression and sup-
port a precursor-cancer relationship between clear cell 
AF and CA with APT as an intermediate step. 
The CA(AF-)s with endometriosis, which tended 
to be cystic, in the present study were significantly 
associated with atypical endometriosis. In some cases, 
there was a morphologic continuum within the epi-
thelium of the endometriotic cyst, in which a gradual 
progressive transition between typical endometriosis, 
atypical endometriosis, and CA could be seen. It  is 
noteworthy that prior studies have shown a higher 
frequency  of  atypia  in  endometriosis  when  a 
co-existent  clear  cell  CA  is  present.17,42,50,70  Atypical 
endometriosis also exhibits a Ki-67 proliferation index 
intermediate between typical endometriosis and clear 
cell CA.72 A large number of molecular and chromo-
somal alterations have been identified in typical and 
atypical  endometriosis/endometriotic 
cysts.2,3,21,26-28,32,36,48,57,67,69  Moreover,  an  atypical  en-
dometriotic cyst recurring as clear cell CA has been 
reported.46  These  observations  provide  strong  evi-
dence that a subset of clear cell CAs arise via the de-
velopment of atypia in an endometriotic cyst as op-
posed to non-cystic endometriosis.  
It must be emphasized, however, that occasional 
APTs and CA(AF+)s in our study also exhibited en-
dometriosis in the ovarian tumor, including atypical 
endometriosis  and  tumor  arising  directly  within  an 
endometriotic  cyst.  Prior  series  have  also  described 
endometriosis specifically within some clear cell AFs, 
an  APT,  and  CA(AF+)s.4,46,55,70,77  Thus,  endometrio-
sis-associated  and  adenofibromatous  pathways  of 
development of clear cell  CA are not entirely inde-
pendent of one another. As the origin of clear cell AF 
has not been previously proven, particularly as there 
is  no  clear  cell  counterpart  in  the  normal  ovary  to 
serve as a precursor, we believe that non-cystic en-
dometriosis (as opposed to an endometriotic cyst) is 
the precursor of clear cell AF. 
We, therefore, propose that endometriosis is the 
underlying  precursor  for  both  the  cystic  and  the 
adenofibromatous types of clear cell CA (Fig. 8). The 
cystic CAs arise from an endometriotic cyst in which Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
103 
atypia develops (i.e., atypical endometriosis, possibly 
representing intraepithelial CA). In the adenofibrom-
atous  pathway,  we  speculate  that  non-cystic  endo-
metriosis induces a fibromatous stromal reaction re-
sulting in the formation of clear cell AF. With further 
glandular proliferation, it progresses to an APT which 
subsequently  develops  into  an  invasive  carcinoma, 
possibly through intraepithelial carcinoma. It should 
be noted that evolution into different forms of clear 
cell neoplasia based on the type of endometriosis from 
which it arose (cystic vs. non-cystic endometriosis) is 
also  indirectly  supported  by  the  demonstration  of 
differences  in  the  clinical  features  of  women  with 
cystic vs. non-cystic endometriosis of the ovary.68  
 
 
 
Figure 8   Proposed model of pathogenesis of ovarian clear cell carcinoma, in which the majority of lesions develop along 
1 of 2 pathways. Non-cystic endometriosis (solid green circle) progresses through either an endometriotic cyst pathway (blue) 
or adenofibromatous pathway (red). In the endometriotic cyst pathway, endometriosis forms an endometriotic cyst and, 
through epithelial atypia (atypical endometriosis), develops into clear cell carcinoma. In the adenofibromatous pathway, we 
speculate a fibromatous reaction, which frequently accompanies endometriosis, could result in the development of a clear 
cell adenofibroma, which subsequently progresses to an atypical proliferative (borderline) clear cell tumor and then to clear 
cell carcinoma. Black dashed arrow, occasional adenofibromatous tumors may arise from an endometriotic cyst as opposed 
to non-cystic endometriosis. 
 
 
As about half of the CAs in this study did not 
contain endometriosis in the ovarian tumor or adeno-
fibromatous  components  (features  of  the  type  I 
pathway),  we  acknowledge  that  other  pathways  of 
tumor development may exist. Similar to the patho-
genesis of serous carcinoma, it has been proposed that 
endometrioid and transitional cell tumors also follow 
low-  and  high-grade  pathways  of  pathogenesis.11,18 
However,  ovarian  clear  cell  CA  has  p53  mutations 
only  infrequently,  and  it  usually  exhibits  a  low  to 
moderate  level  of  chromosomal  instabil-
ity.1,9,14,16,22,37,38,51,52,71 Thus, it is unlikely that a signifi-
cant proportion of clear cell CAs evolve through the 
type II pathway. Also, a small number of clear cell 
CAs in this study contained a mixed carcinoma com-
ponent of non-clear cell type. While it is possible that 
clear cell CA evolved from such mixed non-clear cell 
components,  several  of  those  cases  also  had  either 
adenofibromatous  elements  or  endometriosis  (i.e., 
precursors of clear cell CA) in the ovarian tumor. The 
clinicopathologic  features  in  clear  cell  CAs  lacking 
endometriosis in the ovarian tumor or adenofibrom-Journal of Cancer 2011, 2 
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atous components in this study suggest that they are 
most likely due to tumor progression and overgrowth 
of the precursor elements.  
Because clear cell CA shares features of both type 
I and type II tumors in the dualistic model of ovarian 
carcinogenesis, placement of clear cell carcinoma into 
one of the two groups has been problematic.40,41,59 The 
step-wise progression sequence of AF, APT, and CA 
in the adenofibromatous pathway of clear cell CA is 
analogous  to  that  of  other  type  I  tumors.  Also,  the 
evolution from an endometriotic cyst is similar to the 
process that occurs in endometrioid CA, a type I tu-
mor. Thus, from a precursor standpoint, both path-
ways  in  the  pathogenesis  of  ovarian  clear  cell  CA 
more closely resemble a type I rather than type II tu-
mor. This interpretation is also reinforced by clear cell 
CA’s  frequent  presentation  as  stage  I,  its  molecular 
profile, and the relatively low-level of chromosomal 
instability,  similar  to  other  type  I  tu-
mors.8,9,14,19,25,32,37,38,40,56,59,65,70,71,75  However,  this  study 
does not resolve the issue that clear cell CAs are often 
high-grade and have poor survival when they are of 
advanced  stage  (features  of  type  II  tu-
mors).8,20,24,25,44,58,64,66  
In summary, both types of clear cell carcinomas, 
adenofibromatous  and  cystic,  appear  to  be  derived 
from  endometriosis.  However,  the  former  develop 
from  non-cystic  endometriosis  and  are  associated 
with adenofibromatous components while the latter 
arise from an endometriotic cyst (endometrioma) and 
are  not  associated  with  an  adenofibromatous  back-
ground. The two pathways are not necessarily mutu-
ally exclusive, as there may be overlap in some cases. 
In any event, both forms of clear cell carcinoma are 
more closely related to type I tumors from a precursor 
standpoint. 
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